Moreover, several researches have shown that in IDH-mutant gliomas, the sphingolipid balance can be additionally shifted towards increasing pro-apoptotic ceramide production or towards decreasing pro-survival S1P production by targeting enzymes involved in the sphingolipid metabolism like SPHK1/2 and ceramidase, which reduces cancer hallmarks in IDH-mutant gliomas (Zaibaq et al., 2022; Dowdy et al., 2020; Tea et al., 2020) (Figure 2B). The gene discussed is SPHK1; the disease is cancer.